Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Novartis

Status: Completed

Conditions: Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation

Study type: Observational

Funder types: Industry

Identifiers

NCT06161051

CINC280AUS16

Details and patient eligibility

About

This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.

Enrollment: 287 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient was aged ≥ 18 years at the time of NSCLC diagnosis.

• Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation.

• Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen:

  • Capmatinib
  • IO agent in monotherapy (e.g., atezolizumab, pembrolizumab)
  • CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed)
  • Combination regimen containing IO and CT agents

• Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner.

• Living or deceased at the time of chart abstraction.

Exclusion criteria

• Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time.
• Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period.
• Participation in clinical trials related to treatment for NSCLC at any timepoint.

Trial design

287 participants in 4 patient groups

Capmatinib

IO monotherapy

Chemotherapy alone

IO + chemotherapy